Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 5/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21906181 | 1.00 | FUCA1 (0.42) | FUCA1DRD4SIGMAR1DRD2DRD3 | |
| SCHEMBL21192878 | 0.87 | GBA1 (0.47) | FUCA1DRD4SIGMAR1DRD2DRD3 | |
| SCHEMBL21193171 | 0.87 | GBA1 (0.47) | FUCA1DRD4SIGMAR1DRD2DRD3 | |
| SCHEMBL30613723 | 0.87 | GBA1 (0.47) | FUCA1DRD4SIGMAR1DRD2DRD3 | |
| SCHEMBL26130663 | 0.87 | GBA1 (0.47) | FUCA1DRD4SIGMAR1DRD2DRD3 | |
| SCHEMBL1591829 | 0.85 | FUCA1 (0.51) | FUCA1DRD4SIGMAR1DRD2DRD3 | |
| SCHEMBL1591825 | 0.85 | FUCA1 (0.51) | FUCA1DRD4SIGMAR1DRD2DRD3 | |
| SCHEMBL25111516 | 0.83 | KDM4E (0.49) | FUCA1ACHEKDM4E | |
| SCHEMBL12703742 | 0.83 | KDM4E (0.49) | FUCA1ACHEKDM4E | |
| SCHEMBL1592053 | 0.83 | KDM4E (0.49) | FUCA1ACHEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-03-13 | — | — | US | disclosed |
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-01-14 | — | — | US | disclosed |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-09-15 | — | — | US | disclosed |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195445-B2 | 2-amino-N-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | FUCA1 2747/4885DRD4 4508/4885SIGMAR1 2837/4885 |
| US-20250084064-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | FUCA1 2747/4885DRD4 4508/4885SIGMAR1 2837/4885 |
| US-11377438-B2 | 2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors | SCN8A, SCN2A, SCN1A | FUCA1 2747/4885DRD4 4508/4885SIGMAR1 2837/4885 |
| US-20220289710-A1 | 2-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN1A | FUCA1 2747/4885DRD4 4508/4885SIGMAR1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.